Successful implementation of a national HLA-B*5701 genetic testing service in Canada - PubMed (original) (raw)
Successful implementation of a national HLA-B*5701 genetic testing service in Canada
R G Lalonde et al. Tissue Antigens. 2010 Jan.
Abstract
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that is used in combination antiretroviral therapy in HIV-infected patients. It is currently recommended as a preferred or an alternative NRTI in antiretroviral-naïve patients. The major toxicity of abacavir is a hypersensitivity reaction (HSR), which occurs in approximately 5% of treated patients. There is a strong association between the human leukocyte antigen (HLA)-B*5701 allele and abacavir HSR, which has allowed for rapid acceptance of genetic screening for HLA-B*5701 in clinical use. Canadian clinicians working in hospital centers with HLA typing capacity opted to launch a pilot project in 2006 to offer the screening test as standard of care to HIV-infected patients. Currently, more than 11,000 HLA-B*5701 tests have been performed, among which 6.3% are positive. Continued efforts have been made to ensure that testing is available to all HIV-infected patients to widen the patients' therapeutic options. HLA-B*5701 screening shows clinical use and preliminary data suggest cost-effectiveness.
Similar articles
- A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK, Brumme ZL, Brumme CJ, Yip B, Phillips EJ, Montaner JS, Harrigan PR. Chui CK, et al. Clin Infect Dis. 2007 Jun 1;44(11):1503-8. doi: 10.1086/517499. Epub 2007 Apr 18. Clin Infect Dis. 2007. PMID: 17479950 Clinical Trial. - Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B. Guo Y, et al. Sci China Life Sci. 2013 Feb;56(2):119-24. doi: 10.1007/s11427-013-4438-8. Epub 2013 Feb 8. Sci China Life Sci. 2013. PMID: 23393027 Review. - HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team. Mallal S, et al. N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135. N Engl J Med. 2008. PMID: 18256392 Clinical Trial. - [HLA-B*5701 and abacavir hypersensitivity reaction].
Servonnet A, Leclercq E, Delacour H, Ceppa F. Servonnet A, et al. Pathol Biol (Paris). 2010 Dec;58(6):e95-100. doi: 10.1016/j.patbio.2008.12.001. Epub 2009 Feb 24. Pathol Biol (Paris). 2010. PMID: 19243901 French. - Abacavir hypersensitivity reaction: an update.
Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE. Hughes CA, et al. Ann Pharmacother. 2008 Mar;42(3):387-96. doi: 10.1345/aph.1K522. Epub 2008 Feb 26. Ann Pharmacother. 2008. PMID: 18303141 Review.
Cited by
- Individualization of antiretroviral therapy.
Pavlos R, Phillips EJ. Pavlos R, et al. Pharmgenomics Pers Med. 2012;5:1-17. doi: 10.2147/PGPM.S15303. Epub 2011 Dec 29. Pharmgenomics Pers Med. 2012. PMID: 23226059 Free PMC article. - Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics.
Grossman I, Miller A. Grossman I, et al. EPMA J. 2010 Jun;1(2):317-27. doi: 10.1007/s13167-010-0020-7. Epub 2010 Jun 9. EPMA J. 2010. PMID: 23199067 Free PMC article. - HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.
Neuman MG, Schneider M, Nanau RM, Parry C. Neuman MG, et al. Int J Hepatol. 2012;2012:760706. doi: 10.1155/2012/760706. Epub 2012 Mar 11. Int J Hepatol. 2012. PMID: 22506127 Free PMC article. - Genetic risk prediction in complex disease.
Jostins L, Barrett JC. Jostins L, et al. Hum Mol Genet. 2011 Oct 15;20(R2):R182-8. doi: 10.1093/hmg/ddr378. Epub 2011 Aug 25. Hum Mol Genet. 2011. PMID: 21873261 Free PMC article. Review. - Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.
Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; Canadian Cohort of HIV Infected Slow Progressors. Kamya P, et al. J Virol. 2011 Jun;85(12):5949-60. doi: 10.1128/JVI.02652-10. Epub 2011 Apr 6. J Virol. 2011. PMID: 21471235 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials